Sign In
Buy WHWK
$4.15
-0.250 (-5.68%)
At Close: Jun 05, 2026
Whitehawk Therapeutics Presents RealâWorld Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neur
SEZ6 expression exceeds that of approved and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for co
Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
04:05pm, Thursday, 28'th May 2026
MORRISTOWN, N.J., May 28, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology
Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload
05:05pm, Thursday, 21'st May 2026
Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC's DXC006 Data at ASCO Reinforce Conviction for CPT113,
Whitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation Summit
08:00am, Wednesday, 20'th May 2026
MORRISTOWN, N.J., May 20, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology t
Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
08:00am, Friday, 15'th May 2026
MORRISTOWN, N.J., May 15, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting
04:25am, Friday, 15'th May 2026
Whitehawk Therapeutics pivots to focus on three next-generation antibody-drug conjugates [ADCs] after selling FYARRO and rebranding from Aadi Bioscience. I downgrade WHWK from 'Strong Buy' to 'Hold' d
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
08:00am, Wednesday, 13'th May 2026
MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologie
Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
08:00am, Thursday, 07'th May 2026
Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 Cash, cash equivalents and short-term investments balance of $123.0 million as of March 31,
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
06:00pm, Sunday, 19'th Apr 2026
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across vari
Scott Giacobello Sells 141,600 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
04:36am, Sunday, 19'th Apr 2026
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) CFO Scott Giacobello sold 141,600 shares of the business's stock in a transaction on Thursday, April 16th. The stock was sold at an averag
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
04:05pm, Thursday, 16'th Apr 2026
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biolog
Bryan Ball Sells 6,596 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
05:00am, Wednesday, 15'th Apr 2026
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) insider Bryan Ball sold 6,596 shares of the business's stock in a transaction on Friday, April 10th. The stock was sold at an average pric
Bryan Ball Sells 50,000 Shares of Whitehawk Therapeutics (NASDAQ:WHWK) Stock
04:27am, Wednesday, 15'th Apr 2026
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK - Get Free Report) insider Bryan Ball sold 50,000 shares of the company's stock in a transaction dated Thursday, April 9th. The stock was sold at an average
MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most aggressive and most common subtypes
